{
    "clinical_study": {
        "@rank": "43713", 
        "acronym": "MicroB2", 
        "arm_group": [
            {
                "arm_group_label": "Type2 Diabetes Mellitus", 
                "arm_group_type": "Active Comparator", 
                "description": "Type 2 Diabetes Mellitus (36 completers)\n12 subjects will receive the synbiotic\n12 subjects will receive sevelamer\n12 subjects will receive maltodextrin (placebo)"
            }, 
            {
                "arm_group_label": "Obese with NGT", 
                "arm_group_type": "Active Comparator", 
                "description": "Obese (BMI = 30-37 kg/m2) normal glucose tolerant (36 completers)\n12 subjects will receive the synbiotic\n12 subjects will receive sevelamer\n12 subjects will receive maltodextrin (placebo)"
            }, 
            {
                "arm_group_label": "Lean with NGT", 
                "arm_group_type": "Active Comparator", 
                "description": "Lean (BMI< 26 kg/m2) normal glucose tolerant (36 completers)\n12 subjects will receive the synbiotic\n12 subjects will receive sevelamer\n12 subjects will receive maltodextrin (placebo)"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine whether microbiome modulation and an experimental\n      reduction in plasma LPS concentration improve inflammation and insulin action in insulin\n      resistant (obese and T2DM) subjects."
        }, 
        "brief_title": "Mechanism of Microbiome-induced Insulin Resistance in Humans (Aim2)", 
        "condition": "Insulin Sensitivity", 
        "condition_browse": {
            "mesh_term": "Insulin Resistance"
        }, 
        "detailed_description": {
            "textblock": "In this Aim we will test the hypothesis that lowering LPS concentration in the circulation\n      will improve systemic (muscle) inflammation and glucose metabolism in insulin resistant\n      (obese and T2DM) subjects by protecting the intestinal barrier with a synbiotic\n      (bifidobacterium and oligofructose) or by sequestering LPS in the gastrointestinal lumen\n      with sevelamer."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Both genders (50%, male). All races and ethnic groups.\n\n          -  Premenopausal women in the follicular phase, non-lactating, and with a negative\n             pregnancy test. Postmenopausal women on stable dose of or not exposed to hormone\n             replacement for \u22656 months.\n\n          -  HCT\u2265 34%, serum creatinine \u2264 1.4 mg/dl, and normal results of serum electrolytes,\n             urinalysis, and coagulation tests. LFTs up to 2X.\n\n          -  Stable body weight (\u00b12%) for \u2265 3 months.\n\n          -  Two or less sessions of strenuous exercise/wk for last 6 months.\n\n        Exclusion Criteria:\n\n          -  Current treatment with drugs known to affect glucose and lipid homeostasis. If the\n             subject has been on a stable dose for the past 3 months, the following agents will be\n             permitted: calcium channel blockers, \u03b2-blockers, ACE inhibitors, angiotensin receptor\n             blockers, and statins\n\n          -  History of allergy to sevelamer.\n\n          -  Non-steroidal anti-inflammatory drugs or systemic steroid use for more than a week\n             within 3 months.\n\n          -  Current treatment with anticoagulants (warfarin). Aspirin (up to 325 mg) and\n             clopidogrel will be permitted if these can be held for seven days prior to the biopsy\n             in accordance with the primary physician.\n\n          -  Use of agents that affect gut flora (e.g. antibiotics, colestyramine, lactulose, PEG)\n             within 3 months.\n\n          -  History of heart disease (New York Heart Classification greater than grade II; more\n             than non-specific ST-T wave changes on the ECG), peripheral vascular disease,\n             pulmonary disease, smokers.\n\n          -  Poorly controlled blood pressure (systolic BP>170, diastolic BP>95 mmHg).\n\n          -  Active inflammatory, autoimmune, hepatic, gastrointestinal, malignant, and\n             psychiatric disease.\n\n          -  History of gastrointestinal surgery or gastrointestinal obstruction within two years."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "108", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 24, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02127125", 
            "org_study_id": "HSC20130458H"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Type2 Diabetes Mellitus", 
                    "Obese with NGT", 
                    "Lean with NGT"
                ], 
                "description": "Maltodextrin treatment as a placebo group. Maltodextrin, 6 gm three times a day for 4 weeks.", 
                "intervention_name": "Maltodextrin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Type2 Diabetes Mellitus", 
                    "Obese with NGT", 
                    "Lean with NGT"
                ], 
                "description": "Synbiotic [5 g of oligofructose + 1 g Bifidobacterium longum (4 billion CFU/g) three times a day] for 4 weeks.", 
                "intervention_name": "Synbiotic", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Type2 Diabetes Mellitus", 
                    "Obese with NGT", 
                    "Lean with NGT"
                ], 
                "description": "Sevelamer (1.6 g sevelamer + 4.4 g maltodextrin three times a day), for 4 weeks", 
                "intervention_name": "Sevelamer", 
                "intervention_type": "Drug", 
                "other_name": "Renvela"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Sevelamer"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "April 28, 2014", 
        "location": {
            "contact": {
                "email": "Musi@uthscsa.edu", 
                "last_name": "Nicolas Musi, MD.", 
                "phone": "210-630-5001"
            }, 
            "contact_backup": {
                "email": "sathavarodom@uthscsa.edu", 
                "last_name": "Nattapol Sathavarodom, RA.", 
                "phone": "210-861-7224"
            }, 
            "facility": {
                "address": {
                    "city": "San Antonio", 
                    "country": "United States", 
                    "state": "Texas", 
                    "zip": "78229"
                }, 
                "name": "Audie L. Murphy VA Hospital, STVHCS"
            }, 
            "investigator": {
                "last_name": "Nicolas Musi, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "official_title": "Mechanism of Microbiome-induced Insulin Resistance in Humans (Aim2)", 
        "overall_contact": {
            "email": "musi@uthscsa.edu", 
            "last_name": "Nicolas Musi, MD.", 
            "phone": "210-630-5001"
        }, 
        "overall_contact_backup": {
            "email": "sathavarodom@uthscsa.edu", 
            "last_name": "Nattapol Sathavarodom, RA.", 
            "phone": "210-861-7224"
        }, 
        "overall_official": {
            "affiliation": "The University of Texas Health Science Center at San Antonio", 
            "last_name": "Nicolas Musi, MD.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "July 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Insulin sensitivity", 
            "safety_issue": "No", 
            "time_frame": "Change from baseline insulin sensitivity at 28 days of the intervention."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02127125"
        }, 
        "responsible_party": {
            "investigator_affiliation": "The University of Texas Health Science Center at San Antonio", 
            "investigator_full_name": "Nicolas Musi, MD", 
            "investigator_title": "Nicolas Musi", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Plasma LPS, LBP, soluble CD14, IL-6, and TNF-alpha.", 
                "measure": "Plasma endotoxin level and its panel.", 
                "safety_issue": "No", 
                "time_frame": "Change from baseline plasma endotoxin level and it's panel during 28 days."
            }, 
            {
                "description": "urine for lactulose and mannitol ratio.", 
                "measure": "Gut permeability", 
                "safety_issue": "No", 
                "time_frame": "Change from baseline gut permeability at 24 days of the intervention."
            }
        ], 
        "source": "The University of Texas Health Science Center at San Antonio", 
        "sponsors": {
            "collaborator": {
                "agency": "American Diabetes Association", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "The University of Texas Health Science Center at San Antonio", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}